SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 11.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 407,378 shares of the company’s stock after selling 52,960 shares during the quarter. Victory Capital Management Inc. owned approximately 0.97% of SI-BONE worth $5,711,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. FMR LLC boosted its position in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Mainstream Capital Management LLC acquired a new position in SI-BONE during the fourth quarter worth about $53,000. R Squared Ltd acquired a new position in SI-BONE during the fourth quarter worth about $73,000. Walleye Capital LLC acquired a new position in SI-BONE in the 3rd quarter valued at about $144,000. Finally, Proficio Capital Partners LLC acquired a new position in SI-BONE in the 4th quarter valued at about $155,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Truist Financial reissued a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE presently has an average rating of “Buy” and an average target price of $24.50.

Insider Activity at SI-BONE

In related news, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares of the company’s stock, valued at approximately $3,097,114.60. This trade represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,311 shares of company stock worth $130,356. Company insiders own 3.90% of the company’s stock.

SI-BONE Price Performance

SI-BONE stock opened at $14.75 on Friday. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $19.16. The stock has a market capitalization of $626.18 million, a P/E ratio of -16.03 and a beta of 1.17. The firm’s 50-day moving average is $16.54 and its two-hundred day moving average is $14.87. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE (NASDAQ:SIBN) last released its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $49.00 million for the quarter, compared to analysts’ expectations of $48.87 million. Equities analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.